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INTRODUCTION
T cell activation is initiated by interaction of
antigen-specific receptors with antigen related structures
on the surface of antigen-presenting cells. Prior to CD4+ T
cell activation, antigens must be processed with lysosomal
proteases after endocytosis, then these epitopes are
presented to CD4+ T cells in association with class II
molecules of the major histocompatibility complex (MHC)
(1, 2). However, the proteases responsible for the
antigen-processing have not been well defined. We
developed a specific inhibitor of cathepsin B, the
lysosomal cysteine protease, and this inhibitor, CA074,
selectively inhibits the activity of cathepsin B in vivo as
well as in vitro (3, 4). Matsunaga et al . first reported that
CA074 suppresses immune responses, especially the
production of antigen-specific IgG1 or IgE (5, 6). These
findings suggest that cysteine proteases in lysosomes play
a key role in the functional differentiation of MHC class II
restricted CD4+ T cells which promote IgG1 and IgE
antibody production.
Mice resistant to infection with Leishmania major (L.
major) such as DBA/2, C3H, CBA or C57BL/6 strains
develop T helper (Th) type 1 CD4+ T cells specific for L.
major antigens (7, 8). Th1 cells generate interleukin 2
(IL-2) and interferon γ (IFN-γ), and support the production
of antigen-specific IgG2a type antibody (9, 10). In contrast,
susceptible BALB/c mice develop Th2 CD4+ T cells which
generate IL-4 and IL-5, and which support production of
specific antibodies of the IgE and IgG1classes. However,
the mechanisms involved in the preferential development
of antigen-specific Th1 or Th2 type CD4+ T cells remain to
be defined.
In the present study, we examined the influence of the
inhibition of cathepsin B activity on murine leishmaniasis
to elucidate the participation of lysosomal cysteine
proteases in the functional differentiation of Th1 and Th2
cells. We showed that modulation in antigen-processing
by a cathepsin B inhibitor suppresses the functional
differentiation of Th2 type CD4+ lymphocytes which
augment Th1 type immune responses. These findings
indicate that lysosomal cathepsin B may be involved in
processing antigenic peptides to create a motif that
selectively induces Th2 type immune responses.
MATERIALS AND METHODS
Animals : Female BALB/c CrSlc (BALB/c) and DBA/2
CrSlc (DBA/2) were purchased from Japan Shizuoka
Laboratory Animal Center (SLC) (Hamamatsu, Japan),
and CB-17 scid/scid (SCID) mice were obtained from the
Central Institute for Experimental Animals (Kawasaki,
Japan). The animals were 8-10 weeks of age at the
beginning of experimentation.
Parasites : Cultures of Leishmania major (MHOM/SU/
73/5 ASKH) were provided by Dr. Furuya, Kochi Medical
College, Japan. The parasites were propagated in
Schneider medium containing 20% fetal bovine serum
(GIBCO BRL, Grand Island, NY). Promastigotes were
harvested from stationary-phase cultures by centrifugation
and washed at least three times in PBS. Parasites were
passed at intervals in BALB/c female mice to ensure that
virulence was maintained.
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Antigens and Reagents : Antigens were prepared
using stationary-phase promastigotes of L. major. Soluble
leishmanial antigen (SLA) was prepared as described (11)
and the protein concentration determined using the
Bicinchoninic Acid (BCA) protein assay reagent (Pierce,
Rockfold, IL). Cysteine protease inhibitors, E64d and
CA074, were synthesized in our laboratory. The
specificities of inhibitors were confirmed as described
(3,4). In short, E64d is specific for cathepsin B, H and L,
whereas CA074 is specific only for cathepsin B. E64d was
dissolved in dimethylsulfoxide at a concentration of
10 mg/ml and diluted in PBS at serial concentrations
before use. CA074 was dissolved in PBS. E64d or CA074
was administered at doses of 1 and 0.5 mg/mouse/day,
respectively. Inhibitors were given 2 hr before inoculation
of the parasites and administration of the inhibitors was
continued every 12 hr for the indicated periods.
Establishment and assessment of infection : Mice were
inoculated with L. major subcutaneously in the footpads.
For primary infection, 5 x 106 promastigotes were injected
into the left hind footpad and for rechallenge, the same
number of promastigotes were injected into the right hind
footpad 60 days after the onset of the first infection. The
progression of infection was assessed by monitoring
lesion development by measuring the footpad thickness
with a vernier caliper (Mitsutoyo, Japan).
In vitro L. major proliferation assay : Promastigotes of
L. major 1 x 106/ml) were cultured in Schneider medium
containing 20% fetal bovine serum with or without cysteine
protease inhibitor for 72 hr at 25℃. The proliferation of L.
major was evaluated by counting the parasites every 24 hr.
Measurement of serum immunoglobulin by ELISA : SLA
was covalently coated onto 96-well CovaLink NH plates
(Nunc, Kastrup, Denmark). After blocking with 0.1%
bovine serum albumin in PBS, serum samples serially
diluted with PBS were incubated in the plates for
6 hr at 4℃. The results were visualized using alkaline
phosphatase-conjugated mAb, anti-mouse IgG (Sigma
Chemical Co., St. Louis, MO), anti-mouse IgG1or IgG2a
(Organon Teknika Co., West Chester, PA), or anti-mouse
IgE (Southern Biotechnology Associates, Inc., Bir-
mingham, AL) followed by p-nitrophenyl phosphate
(Sigma). After terminating the reaction with 3N, NaOH,
the optical absorbance at 415 nm was determined on a
microplate reader.
Measurement of cytokine production : Cells from popliteal
lymph nodes draining the footpad lesions were cultured
with SLA (20 μg/ml) for 72 hr. IFN-γ and IL-4 production
in the supernatants were measured using ELISA
EM-IFNG (IFN-γ) and EM-IL 4 (IL-4) kits (ENDOGEN,
Cambridge, MA).
RT-PCR assay : The expression of some cytokines was
evaluated by RT-PCR assay. Interleukin 12 (IL-12) and
interferon γ inducing factor (IGIF) were measured
using peritoneal macrophages. Mice were injected
peritoneally with 10% proteose peptone (DIFCO, Detroit,
MI) to induce macrophages. Four days later, induced
peritoneal macrophages were stimulated with 10 μg/ml
lipopolysaccharide (LPS) and 500 U/ml recombinant
mouse interferon γ (Boehringer Mannheim, Mannheim,
Germany) for the indicated periods. Thereafter, total
RNA was extracted with ISOGEN (Wako, Osaka, Japan).
The RNA was reverse-transcribed using hexanucleotide
random primers (Boehringer Mannheim) in a reaction
mixture (Takara Shuzo, Tokyo, Japan), then the cDNA
was amplified with Taq DNA polymerase (Takara Shuzo).
The thermocycle conditions were 35 cycles of 95℃
for 1 min, 55℃ for 1 min, anda 72℃ for 1 min, for
denaturing, annealing and extension, respectively. The
primer sequenceswere, 5'-CGTGCTATGGCTGGTGCAAAG-
3' and 5'-GAACACATGCCCACTTGCTG-3' for p 40
subunit of IL-12,, 5'-ACTGTACAACCGCAGTAATACGG-
3' and 5'-AGTGAACATTACAGATTTATCCC-3' for
IGIF, and 5'-ATGGATGACGATATCGCT-3' and 5'-
ATGAGGTAGTCTGTCAGGT-3' for β-actin, respectively.
Amplified DNAs were resolved by means of 2% agarose
gel electrophoresis and stained with ethidium bromide.
The early IL-4 was also estimated by RT-PCR assay. Mice
were injected with 0.5 ml 2 C 11 culture supernatant
including anti-CD 3 monoclonal antibody and spleen cells
were taken 1 hr after injection. RNA extraction and
reverse-transcription proceeded as described above.
The thermocycle conditions were 30 cycles as described
above for IL-12 and IGIF. The primer sequences for
IL-4 were 5'-CTTCTTTCTCGAATGTACCAGG-3' and 5'-
GTTAAAGCATGGTGGCGCAGTAC-3'.
RESULTS
Effect of cysteine protease inhibitor on progression of
leishmaniasis
The cysteine protease inhibitor, E64d, has an inhibitory
effect on several lysosomal cysteine proteases, cathepsin
B, L and H. We examined the effect of E64d on the
progression of murine leishmaniasis. Five million
promastigotes of L. major were subcutaneously inoculated
into the left hind footpad and for 6 weeks 1 mg/day (0.5
mg/12 hrs) of E64d was administered intraperitoneally.
Footpad swelling was measured to evaluate the
progression of infection. As shown in Fig.1, footpad
swelling progressed in PBS-treated BALB/c mice. BALB/c
mice given E64d after infection did not develop further
footpad swelling, suggesting that cysteine protease
inhibitor controlled L. major infection in susceptible BALB/c
mice. In DBA/2 mice which are H-2 compatible with
BALB/c mice but resistant to leishmaniasis, E64d did not
allow the disease to progress to the extent as in
PBS-treated DBA/2 mice.
E64d has a broad inhibitory effect on cysteine proteases
such as cathepsin B, L and H. To define the most active
component of E64d, it is essential to use a more specific
inhibitor. We therefore examined the effect of the
inhibitor specific only for cathepsin B, CA074, on murine
leishmaniasis. Cathepsin B is a lysosomal cysteine
protease that is involved in antigen processing (6, 12). In
comparison with PBS-treated BALB/c mice that showed
progressive footpad swelling, BALB/c mice treated with
CA074 [0.5 mg/day (0.25 mg/12 hrs)] showed resistance
against L. major infection to a similar degree as BALB/c
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mice given E64d (Fig.2 a). Thus, cathepsin B is
specifically involved with acquisition of resistance against
L. major infection. Therefore, we used CA074 in all of the
remaining experiments.
No direct influence of the cysteine protease inhibitor on L.
major protozoa
The cysteine protease inhibitor could have been
cytotoxic against L. major protozoa. To exclude this
possibility, we examined the direct influence of CA074 on
the in vitro proliferation of L. major promastigotes.
As shown in Fig.3 a, L. major proliferated comparably
regardless of presence or absence of CA074.
We then investigated whether or not this inhibitor
influenced the in vivo growth of these protozoa in SCID
mice which are deficient in functional T and B cells. As
shown in Fig.3 b, no difference in lesional footpad
thickness was observed between PBS-and CA074-treated
SCID mice. In addition, the speed of progression and
pattern of lesions were similar between protease
inhibitor-treated or untreated nude mice (data not shown).
Thus, cathepsin B-specific inhibitor did not directly
influence the infectivity of L. major, suggesting that the
resistance against L. major infection by treatment with
cathepsin B-specific inhibitor was acquired through an
immunologic mechanism lacking in the SCID mice, e.g. T
cell-mediated immunity. Furthermore, this resistance was
not attenuated in E64d-treated DBA/2 mice which are H-2
compatible with BALB/c mice but resistant to L. major
infection . These findings indicate that cysteine
proteaseSCID inhibitor does not exert suppressive effects
on immunity in DBA/2 mice and the suppressive action in
BALB/c mice does not depend on the MHC.
Re-infection with L. major in BALB/c mice treated with
CA074
We then investigated the mechanisms of resistance in
BALB/c mice treated with cathepsin B-specific inhibitor.
Fig. 1. Progression of infection with Leishmania major in mice
treated with cysteine protease inhibitors.
Eight week-old female BALB/c mice (circles) and DBA/2 mice
(squares) were inoculated with 5 x 106 L. major promastigotes in
the left hind footpad. Cysteine protease inhibitor, E64d (1 mg/day
(0.5 mg/12 hr) (filled symbols), or PBS as control (open symbols)
were then administered for 6 weeks. The progression of infection
was evaluated by measuring with calipers the relative lesional
swelling at 1 week intervals.
Fig. 2. Cathepsin B-specific inhibitor gives resistance in mice
infected with L. major
a. Eight week-old female BALB/c mice were inoculated with
5 x 106 L. major promastigotes in the left hind footpad. Cysteine
protease inhibitor, E64d [1 mg/day (0.5 mg/12 hr)] (filled circles),
CA074 [0.5 mg/day (filled squares) or PBS as control (open
circles) were administered for 40 days after inoculation. The
progression of infection was evaluated by measuring the relative
lesional swelling at 10 day intervals. b. Naive age-matched female
BALB/c (open squares), PBS-treated BALB/c (open circles) and
CA074-treated mice (closed circles) were inoculated with 5 x 106
promastigotes of L. major in the contralateral (right) hind footpad.
The progression of infection was evaluated by measuring absolute
lesional footpad thickness at 10 day intervals.
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Infected BALB/c mice treated with CA074 or PBS were
later re-infected via the contralateral footpad 60 days after
the onset of primary infection. Re-infected mice were not
given further CA074 (Fig.2 b). Swelling at the re-infected
footpad prominently progressed in naive and PBS-treated
BALB/c mice, whereas CA074-treated BALB/c mice were
completely resistant whether or not additional CA074 had
been given. Thus, infected BALB/c mice treated with
CA074 had acquired protective immunity that was
probably mediated by T cells.
Serum immunoglobulin in CA074 -treated BALB/c mice
CD4+ T cells can be classified into two functionally
different Th1 and Th2 subsets. Th1 and Th2 individually
support immunoglobulin class-switching. The production
of IgG1 and IgE antibodies is supported by Th2 cells, while
the response of IgG2a antibodies is supported by Th1 cells.
In murine leishmaniasis, Th1 cells are protective T cells
that support the production of IgG2a in the resistant mice,
while Th2 cells are disease-promoting T cells that support
IgG1 and IgE antibody responses. We examined the
proportion of each subclass of L. major -specific antibody
in the serum to evaluate the immunological status of
infected mice (Fig.4). No difference in the amount of L.
major -specific IgG between PBS-and CA074-treated BALB/c
mice was observed. The amount of IgG2a was slightly
higher in CA074 than in PBS-treated mice. In contrast, the
production of IgG1 and IgE antibodies promoted by Th2
cells was markedly suppressed in the CA074-treated mice
as compared with that in PBS-treated mice, indicating that
Th2 function had been inhibited by the cathepsin B
specific inhibitor.
The functional phenotype of T cells in CA074 -treated
BALB/c mice
We examined the functional phenotype of CD 4+ T cells
in BALB/c mice that acquired resistance against L. major
infection after treatment with the cathepsin B-specific
inhibitor, CA074. Cells from lymph nodes draining the
footpad lesions of infected mice were stimulated with
soluble L. major antigen, and the titers of each cytokine in
the culture supernatants was assessed by ELISA (Fig.5).
Fig. 3. Direct influence of cathepsin B specific inhibitor on L. major
protozoa.
a. Stationary phase of L. major promastigotes (1 x 106) were
cultured in Schneider medium containing 20% fetal bovine serum
with CA 074 (open squares, 0 μg/ml ; filled circles, 1 μg/ml ; filled
triangles, 10 μg/ml ; filled squares, 100 μg/ml). The parasites were
counted at 24 hr intervals by light microscope. Three individual
experiments were performed and the results were the same in each
experiment. b. Eight week-old female CB-17 scid/scid mice were
inoculated with 5 x 106 L. major promastigotes in the left hind
footpad. Cysteine protease inhibitor, CA074 [0.5 mg/day (0.25 mg/
12 hr)] (filled circles) or PBS as control (open circles) were
administered for 40 days after inoculation. The progression of
infection was evaluated by measuring the relative lesional swelling
at 10 day intervals.
Fig. 4. Isotypes of antibodies specific for L. major antigens in
BALB/c mice treated with CA 074.
Sera were obtained from PBS-treated mice (open columns) or
CA074-treated mice [0.5 mg/day(0.25 mg/12 hr) for 20 days]
(closed columns) mice 20 days after infection. Isotype of the
antigen-specific immunoglobulin was assayed by ELISA as
described in Material and Methods.
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Production of IL-4 or IFN-γ indicates Th2 or Th1
responses, respectively. High levels of IL-4, but not of
IFN-γ were produced in PBS-treated mice. In contrast,
CA074 increased IFN-γ production and decreased
production of IL-4. Thus, the cytokine produced in
PBS-treated mice was of the Th2 type, rather than the Th1
type in CA074-treated mice. These findings suggest that
Th2 function had been suppressed in BALB/c mice by
treatment with the cathepsin B inhibitor so that Th1
function could be sufficiently activated to resolve infection
by L. major. Thus, inactivation of cathepsin B appears to
inhibit the development of Th2 type immune responses
that ordinarily develop in BALB/c mice infected with L.
major, and as a result promotes the development of Th1
cells. In other words, cathepsin B in the lysosomes of
antigen-presenting cells processes antigens of L. major
which acts to promote exclusively the development of Th2
type CD 4+ T cells.
No direct influence of cathepsin B -specific inhibitor on factors
that promote the development of Th1 type immune responses
Many factors, especially cytokines, regulate the func-
tional differentiation of CD 4+ T cells. IL-12, a cytokine
produced by APCs, is a powerful mediator that induces
Th1 type differentiation (13, 14, 15). Furthermore, IGIF
(IFN-γ inducing factor) cloned by Okamura et al. induces
IFN-γ production by T cells (16). IL-12 and IGIF are
produced by macrophages upon stimulation with LPS plus
IFN-γ. We evaluated the influence of CA074 on IL-12 and
IGIF production by macrophages using RT-PCR (Fig.
6 a). When the proteose peptone-induced peritoneal
macrophages of BALB/c mice were stimulated with LPS
plus IFN-γ in vitro , IL-12 p40 subunit mRNA expression
was induced 6-12 hours following stimulation. This
expression profile was not affected by adding CA074 to
LPS plus IFN-γ treated cells. CA074 also had no direct
influence on the expression of IGIF mRNA. Exposure to
IL-4 at an early stage of the immune response promotes
Th2 development (17) while extinction of IL-4 effect by
anti-IL-4 antibody leads to Th1 development (18). This
early IL-4 response is generated by NK 1.1+ T cells as
described (17, 19). We investigated the influence of
CA074 on production of IL-4 in mice that had also been
injected with anti-CD3 monoclonal antibody. As shown in
Fig.6 b, IL-4 production was not reduced by treatment
with CA074. These data indicate that the cathepsin B
specific inhibitor, CA074, does not alter appreciably the
environment including cytokine factors which promote
the development of Th1 cells.
DISCUSSION
We show here that both generic and specific cathepsin
B inhibitors interfere with the Th2 type immune response
which ordinarily develops in BALB/c mice infected with
Leishmania major (L. major), disease-promoting Th2 type
CD 4+ T cells that preferentially appear after the infection.
When susceptible BALB/c mice infected with this
protozoan were treated with a specific inhibitor for
cathepsin B, they completely resolved their infection. This
acquired resistance was not due to a direct cytotoxic effect
on the L. major protozoan, but to the switch of Th
cell-mediated immune responses from disease-promoting
Th2 to protective Th1 type as evaluated by cytokine
production, specific antibody production, or antibody
responses in the different Ig classes. Thus, cathepsin B
Fig. 5. Cytokine profiles of LN cells in BALB/c mice treated with
CA074.
Two million lesional LN cells from PBS-treated mice (open
column) and CA074-treated mice [0.5 mg/day (0.25 mg/12 hr) for
20 days] (closed column) 20 days after infection were stimulated
with soluble leishmanial antigen (20 μg/ml) for 72 hr. IFN-γ or IL-4
in culture supernatants were assayed using EM-IFNG and EM-IL4
ELISA kits, respectively. Titrations were based on standard curves.
Fig. 6．Cysteine protease inhibitor does not directly affect the cytokine production that regulates Th differentiations.
a. Proteose peptone-induced peritoneal macrophages were stimulated in vitro with LPS(10 μg/ml) and rIFN-γ (500 U/ml) and/or CA074
(10 μg/ml) for the indicated periods. Thereafter, cells were harvested and total mRNA was extracted as described in Material and Methods.
The mRNA expression of IL-12 p40 subunit and IGIF were evaluated by PCR. b. Eight week-old female BALB/c mice were injected with 0.5 ml
2C11 culture supernatant. One hour after stimulation, total mRNA was extracted from splenocytes and RT-PCR was performed to detect IL-4
mRNA as described in Material and Methods.
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inhibitor appears to block the development of the Th2
type immune response which ordinarily develops in
BALB/c mice infected with L. major, and also promotes
the development of Th1 cells.
Many factors, especially cytokines, regulate the
functional differentiation of CD 4+ T cells. Alterations
in the cytokine environment changes the Th1/
Th2 balance as has been shown by other studies of
murine leishmaniasis. Thus, IFN-γ and IL-4 reciprocally
counter-regulate the differentiation of Th1 and Th2
cells from their precursor cells (Thp). For example,
IFN-γ enhances the development of Th1 but inhibits
development of Th2 cells and administration of
monoclonal anti-IFN-γ antibodies in vivo abrogates the
natural resistance of C 3 H/HeN mice to infection with L.
major (20), whereas IL-4 promotes the opposite effect
(18). IL-12 (13, 14, 15) and interferon γ inducing factor
(IGIF) (16) secreted by macrophages play key roles in the
induction of Th1 responses. From these bases, we
examined whether the cathepsin B inhibitor, CA074,
directly induces IL-12 or IGIF. This possibility was
negated as is shown in Fig.6. IL-4 secreted by NK 1.1+ T
cells promotes the development of Th2 cells (17, 19). We
then examined the influence of CA074 on IL-4 production
from NK 1.1+ T cells in vivo and found that it had
no effect. CD 80 and CD 86 expressed on activated
antigen-presenting cells transfer signals that promote the
differentiation of CD 4+ T cells into Th1 and Th2 T cells,
respectively (21, 22, 23). Accordingly, we investigated,
employing in vitro experiments, whether CA074 influ-
ences expression of these molecules directly. Here we
used LPS-activated B cells but this possibility was also
negated (data not shown).
As shown here, the Th2 response was suppressed
in BALB/c mice infected with L. major and treated
with CA074. The Th1 response essential to protective
immunity against leishmaniasis became dominant in these
animals. A similar effect in mice was induced by cathepsin B
inhibitors when so-called IgE-inducible antigens such as
ovalbumin (5) or Nippostrongylus brasiliensis (data not
shown) were used as antigens. Thus, cathepsin B
inactivation by its specific inhibitor could be expected to
influence immune responses, especially the functional
differentiation of CD 4+ T cells. At present, the detailed
molecular mechanisms responsible for cathepsin B
inactivation and alteration of phenotype from Th2 to Th1
have not been clarified. However, since cysteine
proteases, especially cathepsin B are presumed to be one
of the main lysosomal proteases that process exogenous
antigens in antigen-presenting cells (6, 12), the presented
peptides would be expected to be altered in quality and/
or quantity which in turn could affect Th1/Th2
differentiation.
It is important to elucidate in molecular detail the
switching mechanisms responsible for T cell development
from Th2 to Th1 type immune responses in mice treated
with cathepsin B inhibitors in order to understand the
mechanism(s) underlying CD 4+ T cell differentiation and
the immune deviation towards IgE production often seen
clinically. In addition, experiments using these lysosomal
protease inhibitors may shed light upon whether or not
some antigenic motifs preferentially direct Th2 or Th1
responses and IgE specific antibody production.
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